Biodesix (BDSX) Cash & Equivalents (2019 - 2026)

Biodesix has reported Cash & Equivalents for 8 years, with the latest figure at $25.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 45.27% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $25.6 million (up 45.27% YoY), and the FY2025 full-year result was $19.0 million, down 27.65% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $25.6 million, up from $19.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $43.1 million in Q4 2022, with the low at $11.5 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $23.4 million across 5 years, with a median of $20.7 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 70.36% — and 2024, when it soared 142.51%.
• Biodesix's Cash & Equivalents stood at $43.1 million in 2022, then sank by 39.0% to $26.3 million in 2023, then slipped by 0.15% to $26.2 million in 2024, then declined by 27.65% to $19.0 million in 2025, then jumped by 34.68% to $25.6 million in 2026.
• The last three Cash & Equivalents figures came in at $25.6 million (Q1 2026), $19.0 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.